Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Interferon-gamma in ascites could be a predictive biomarker of outcome in ovarian carcinoma.

Chen YL, Cheng WF, Chang MC, Lin HW, Huang CT, Chien CL, Chen CA.

Gynecol Oncol. 2013 Oct;131(1):63-8. doi: 10.1016/j.ygyno.2013.07.105. Epub 2013 Aug 1.

PMID:
23917082
2.

IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro.

Wall L, Burke F, Barton C, Smyth J, Balkwill F.

Clin Cancer Res. 2003 Jul;9(7):2487-96.

3.

Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma.

Abendstein B, Marth C, Müller-Holzner E, Widschwendter M, Daxenbichler G, Zeimet AG.

Cancer. 2000 Mar 15;88(6):1432-7.

PMID:
10717627
4.

Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.

Bamias A, Koutsoukou V, Terpos E, Tsiatas ML, Liakos C, Tsitsilonis O, Rodolakis A, Voulgaris Z, Vlahos G, Papageorgiou T, Papatheodoridis G, Archimandritis A, Antsaklis A, Dimopoulos MA.

Gynecol Oncol. 2008 Feb;108(2):421-7. Epub 2007 Nov 26.

PMID:
18036640
5.

Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.

Kusuda T, Shigemasa K, Arihiro K, Fujii T, Nagai N, Ohama K.

Oncol Rep. 2005 Jun;13(6):1153-8.

PMID:
15870936
6.

Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer.

Yigit R, Figdor CG, Zusterzeel PL, Pots JM, Torensma R, Massuger LF.

Eur J Cancer. 2011 Aug;47(12):1883-9. doi: 10.1016/j.ejca.2011.03.026. Epub 2011 Apr 20.

PMID:
21514148
7.

Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.

Alberts DS, Marth C, Alvarez RD, Johnson G, Bidzinski M, Kardatzke DR, Bradford WZ, Loutit J, Kirn DH, Clouser MC, Markman M; GRACES Clinical Trial Consortium.

Gynecol Oncol. 2008 May;109(2):174-81. doi: 10.1016/j.ygyno.2008.01.005. Epub 2008 Mar 7.

PMID:
18314182
8.

Expression of IL-10 in patients with ovarian carcinoma.

Mustea A, Könsgen D, Braicu EI, Pirvulescu C, Sun P, Sofroni D, Lichtenegger W, Sehouli J.

Anticancer Res. 2006 Mar-Apr;26(2C):1715-8.

9.

[Assessment of prognostic factors in common ovarian tumors of varying malignancy].

Demeter A, Várkonyi T, Csapó Z, Szánthó A, Oláh J, Papp Z.

Magy Onkol. 2004;48(3):259-65. Epub 2004 Nov 1. Hungarian.

10.

Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.

Giuntoli RL 2nd, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, Oelke M.

Anticancer Res. 2009 Aug;29(8):2875-84.

11.

Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.

Mustea A, Pirvulescu C, Könsgen D, Braicu EI, Yuan S, Sun P, Lichtenegger W, Sehouli J.

Cytokine. 2008 Apr;42(1):77-84. doi: 10.1016/j.cyto.2008.01.011. Epub 2008 Mar 7.

PMID:
18329282
12.

Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors.

Nowak M, Glowacka E, Szpakowski M, Szyllo K, Malinowski A, Kulig A, Tchorzewski H, Wilczynski J.

Neuro Endocrinol Lett. 2010;31(3):375-83.

PMID:
20588232
13.

Functional role and prognostic significance of CD157 in ovarian carcinoma.

Ortolan E, Arisio R, Morone S, Bovino P, Lo-Buono N, Nacci G, Parrotta R, Katsaros D, Rapa I, Migliaretti G, Ferrero E, Volante M, Funaro A.

J Natl Cancer Inst. 2010 Aug 4;102(15):1160-77. doi: 10.1093/jnci/djq256. Epub 2010 Jul 16.

14.

Procollagen-derived biomarkers in malignant ascites of ovarian cancer. Independent prognosticators for progression-free interval and survival.

Cracchiolo BM, Hanauske-Abel HM, Schwartz PE, Chambers JT, Holland B, Chambers SK.

Gynecol Oncol. 2002 Oct;87(1):24-33.

PMID:
12468338
15.

c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.

Tomić S, Ilić Forko J, Babić D, Sundov D, Kuret S, Andelinović S.

Croat Med J. 2003 Aug;44(4):429-34.

16.

Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer.

Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, Buller RE.

Obstet Gynecol. 2002 Jul;100(1):59-64.

PMID:
12100804
17.

Colony-stimulating factor-1 in primary ascites of ovarian cancer is a significant predictor of survival.

Price FV, Chambers SK, Chambers JT, Carcangiu ML, Schwartz PE, Kohorn EI, Stanley ER, Kacinski BM.

Am J Obstet Gynecol. 1993 Feb;168(2):520-7.

PMID:
8438921
18.

The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinoma.

Saygili U, Guclu S, Uslu T, Erten O, Dogan E.

Int J Gynecol Cancer. 2002 Sep-Oct;12(5):438-42.

PMID:
12366659
19.

Serum soluble interleukin-2 receptors in epithelial ovarian cancer patients.

Pavlidis NA, Bairaktari E, Kalef-Ezra J, Nicolaides C, Seferiadis C, Fountzilas G.

Int J Biol Markers. 1995 Apr-Jun;10(2):75-80.

PMID:
7561242
20.

Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks.

Naldini A, Morena E, Belotti D, Carraro F, Allavena P, Giavazzi R.

Thromb Haemost. 2011 Oct;106(4):705-11. doi: 10.1160/TH11-05-0311. Epub 2011 Aug 11.

PMID:
21833453

Supplemental Content

Support Center